LXW7 (TFA)
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].
Product Specifications
UNSPSC
12352209
Target
Integrin
Type
Peptides
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lxw7-tfa.html
Purity
98.44
Solubility
H2O
Smiles
O=C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC(O)=O)C(N[C@@H]1C(C)C)=O)=O)=O)=O)=O)[C@@H](CSSC[C@H](C(N)=O)NC1=O)N.OC(C(F)(F)F)=O
Molecular Formula
C31H49F3N12O14S2
Molecular Weight
934.92
References & Citations
[1]Xiao W, et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther. 2010 Oct;9 (10) :2714-23.|[2]Fang T, et al. LXW7 ameliorates focal cerebral ischemia injury and attenuates inflammatory responses in activated microglia in rats. Braz J Med Biol Res. 2016 Aug 1;49 (9) :e5287.|[3]Hao D, et al. Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. ACS Chem Biol. 2017 Apr 21;12 (4) :1075-1086.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP22513PU-N 50 µg
Ferritin Heavy Chain (FTH1) (221-232) Goat Polyclonal Antibody
Sign In for Pricing
View Details 